Pfizer Inc. (NYSE:PFE) Receives Average Rating of “Hold” from Analysts

Pfizer Inc. (NYSE:PFE) has been assigned an average rating of “Hold” from the thirteen ratings firms that are covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $34.50.

A number of equities research analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, July 10th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Morgan Stanley boosted their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Barclays boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 10th.

Pfizer Stock Performance

NYSE PFE opened at $29.71 on Friday. The firm has a market cap of $168.35 billion, a price-to-earnings ratio of -495.08, a price-to-earnings-growth ratio of 1.15 and a beta of 0.69. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The business has a 50-day moving average price of $28.37 and a 200-day moving average price of $27.75. Pfizer has a twelve month low of $25.20 and a twelve month high of $37.80.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.23 earnings per share. As a group, equities research analysts predict that Pfizer will post 2.39 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.65%. Pfizer’s dividend payout ratio is -2,799.53%.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Clifford Swan Investment Counsel LLC grew its stake in shares of Pfizer by 4.7% during the fourth quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock valued at $12,007,000 after buying an additional 18,611 shares during the last quarter. LifePlan Financial LLC purchased a new position in Pfizer during the 4th quarter worth $255,000. Cantor Fitzgerald Investment Advisors L.P. purchased a new position in Pfizer during the 4th quarter worth $16,166,000. KLCM Advisors Inc. increased its holdings in Pfizer by 75.0% during the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after purchasing an additional 74,487 shares during the period. Finally, Farmers Trust Co. increased its holdings in Pfizer by 2.0% during the 4th quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock worth $6,503,000 after purchasing an additional 4,410 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.